Stock SUPN SUPERNUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Supernus Pharmaceuticals, Inc.

Equities

SUPN

US8684591089

Real-time Estimate Cboe BZX
Other stock markets
 07:43:09 18/06/2024 pm IST 		5-day change 1st Jan Change
26.42 USD +1.64% Intraday chart for Supernus Pharmaceuticals, Inc. +0.23% -9.26%
23/05 Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study MT
23/05 Transcript : Supernus Pharmaceuticals, Inc. - Special Call

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
GL
Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study
MT
Transcript : Supernus Pharmaceuticals, Inc. - Special Call
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
GL
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
PR
Supernus Pharmaceuticals : 817P202 Interim Data Presentation May 2024 Final
PU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
PR
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
GL
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Reports Q1 Revenue $143.6M, vs. Street Est of $145.8M
MT
Supernus Pharmaceuticals, Inc. Seeks M&A
CI
Transcript : Supernus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024
Supernus Announces First Quarter 2024 Financial Results
GL
Supernus Pharmaceuticals, Inc. Reiterates Financial Guidance for the Full Year 2024
CI
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Supernus, M8 Pharmaceuticals Sign Licensing Deal for ADHD Drug Qelbree in Latin America
MT
M8 Pharmaceuticals, an Acino Company, Signs an Exclusive Licensing Agreement with Supernus for Qelbree® (Viloxazine Xr) in Latin America
CI
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
PR
Supernus Pharmaceuticals : 2023 Annual Report
PU
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
BU
Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SUPN Stock
  4. News Supernus Pharmaceuticals, Inc.